MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 15mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 15mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 15mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Stability Notes

Hygroscopic protect from moisture and light. Maximum of 7 days in MCA.

Provenance

This compatibility recommendation is derived from Abilify 30mg tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.